Eli Lilly Tops $1T Market Cap on 70% Six-Month Rally, Raises 2026 Revenue to $83B
Shares of Eli Lilly have climbed about 70% over six months, driven by Q4 sales of $7.41 billion for Mounjaro and $4.3 billion for Zepbound that lifted adjusted EPS to $7.54 on $19.3 billion revenue. It forecasted $80–83 billion revenue for 2026, triggering a 10% share surge that lifted its market cap past $1 trillion.
1. Q4 2025 Performance
In Q4 fiscal 2025, Lilly reported revenue of $19.3 billion and adjusted net income of $7.54 per share, topping consensus estimates of $17.96 billion and $6.67 per share. Sales for Mounjaro reached $7.41 billion, while Zepbound contributed $4.3 billion, driven by strong volume growth.
2. 2026 Financial Guidance
Lilly issued guidance for fiscal 2026 projecting revenue between $80.00 and $83.00 billion and earnings of $33.50 to $35.00 per share, exceeding analyst estimates and signaling continued growth momentum in its obesity and diabetes franchise.
3. Market Capitalization Milestone
Following the guidance release and strong Q4 results, Lilly’s shares jumped roughly 10%, propelling its market capitalization past the $1 trillion mark—the first pharmaceutical company to reach this valuation—after a roughly 70% rally over the past six months.